FDA Working Aggressively On Globalization Strategy – Commissioner
This article was originally published in The Rose Sheet
Executive Summary
Less than a week after the agency’s international regulatory “aggressiveness” was called into question at a Senate appropriations hearing, FDA releases its Global Engagement report, highlighting its accomplishments to date while noting that ensuring the safety of imported products is a “formidable task.”
You may also be interested in...
FDA Flags Chinese Personal-Care Firm For Drug GMP Failings
The agency will pursue cosmetics and personal-care product companies as pharmaceutical manufacturers if their product labeling strays into drug territory. FDA’s warning letter to Shanghai Huhui Daily Use Chemical Products says its skin protectant cream does not comply with the OTC monograph.
FDA Proposes $19 Mil. In Cosmetics User Fees To Support Enhanced Oversight
With almost $19 million in user fees proposed for cosmetics manufacturers in FDA’s budget request, the agency intends to overhaul regulation of the personal-care industry.
FDA Adapts Enforcement Strategy In Increasingly Globalized Market
FDA will overhaul its enforcement approach to reflect the impact of globalization by partnering more with foreign counterparts, streamlining inspections, recalls and emergency responses and using stiff criminal sanctions to deter noncompliance, FDA officials say.